200 related articles for article (PubMed ID: 37200859)
81. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas.
Gruss HJ; Dower SK
Blood; 1995 Jun; 85(12):3378-404. PubMed ID: 7780126
[TBL] [Abstract][Full Text] [Related]
82. Potentiation of Fas-mediated apoptosis of murine granulosa cells by interferon-gamma, tumor necrosis factor-alpha, and cycloheximide.
Quirk SM; Porter DA; Huber SC; Cowan RG
Endocrinology; 1998 Dec; 139(12):4860-9. PubMed ID: 9832422
[TBL] [Abstract][Full Text] [Related]
83. Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells.
de Campos NSP; de Oliveira Beserra A; Pereira PHB; Chaves AS; Fonseca FLA; da Silva Medina T; Dos Santos TG; Wang Y; Marasco WA; Suarez ER
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628256
[TBL] [Abstract][Full Text] [Related]
84. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.
Supimon K; Sangsuwannukul T; Sujjitjoon J; Chieochansin T; Junking M; Yenchitsomanus PT
Cytotherapy; 2023 Feb; 25(2):148-161. PubMed ID: 36396553
[TBL] [Abstract][Full Text] [Related]
85. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
86. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
87. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.
Caldwell SA; Ryan MH; McDuffie E; Abrams SI
J Immunol; 2003 Sep; 171(5):2402-12. PubMed ID: 12928387
[TBL] [Abstract][Full Text] [Related]
88. Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide.
Brossart P; Bevan MJ
J Exp Med; 1996 Jun; 183(6):2449-58. PubMed ID: 8676065
[TBL] [Abstract][Full Text] [Related]
89. Hetero-oligomerization between the TNF receptor superfamily members CD40, Fas and TRAILR2 modulate CD40 signalling.
Smulski CR; Decossas M; Chekkat N; Beyrath J; Willen L; Guichard G; Lorenzetti R; Rizzi M; Eibel H; Schneider P; Fournel S
Cell Death Dis; 2017 Feb; 8(2):e2601. PubMed ID: 28182009
[TBL] [Abstract][Full Text] [Related]
90. Subcutaneous biodegradable scaffolds for restimulating the antitumour activity of pre-administered CAR-T cells.
Zhang DKY; Brockman JM; Adu-Berchie K; Liu Y; Binenbaum Y; de Lázaro I; Sobral MC; Tresa R; Mooney DJ
Nat Biomed Eng; 2024 Jun; ():. PubMed ID: 38831041
[TBL] [Abstract][Full Text] [Related]
91. Context-specific synthetic T cell promoters from assembled transcriptional elements.
Appelbaum J; Wei J; Mukherjee R; Ishida T; Rosser J; Saxby C; Chase J; Carlson M; Sather C; Rahfeldt W; Meechan M; Baldwin M; Flint L; Spurrell C; Gustafson J; Johnson A; Jensen M
Res Sq; 2023 Oct; ():. PubMed ID: 37886484
[TBL] [Abstract][Full Text] [Related]
92. Editorial: Emerging learnings in cell therapy: novel binding domains, universal CAR-T cells, and more.
Rotte A
Front Oncol; 2024; 14():1404376. PubMed ID: 38686191
[No Abstract] [Full Text] [Related]
93. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.
Kawalekar OU; O' Connor RS; Fraietta JA; Guo L; McGettigan SE; Posey AD; Patel PR; Guedan S; Scholler J; Keith B; Snyder NW; Blair IA; Milone MC; June CH
Immunity; 2016 Mar; 44(3):712. PubMed ID: 28843072
[No Abstract] [Full Text] [Related]
94. CAR T therapy beyond cancer: the evolution of a living drug.
Baker DJ; Arany Z; Baur JA; Epstein JA; June CH
Nature; 2023 Jul; 619(7971):707-715. PubMed ID: 37495877
[TBL] [Abstract][Full Text] [Related]
95. Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors.
Neeser A; Ramasubramanian R; Wang C; Ma L
Immunooncol Technol; 2023 Sep; 19():100385. PubMed ID: 37483659
[TBL] [Abstract][Full Text] [Related]
96. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity.
Ma L; Hostetler A; Morgan DM; Maiorino L; Sulkaj I; Whittaker CA; Neeser A; Pires IS; Yousefpour P; Gregory J; Qureshi K; Dye J; Abraham W; Suh H; Li N; Love JC; Irvine DJ
Cell; 2023 Jul; 186(15):3148-3165.e20. PubMed ID: 37413990
[TBL] [Abstract][Full Text] [Related]
97. T cells in health and disease.
Sun L; Su Y; Jiao A; Wang X; Zhang B
Signal Transduct Target Ther; 2023 Jun; 8(1):235. PubMed ID: 37332039
[TBL] [Abstract][Full Text] [Related]
98. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.
Dagar G; Gupta A; Masoodi T; Nisar S; Merhi M; Hashem S; Chauhan R; Dagar M; Mirza S; Bagga P; Kumar R; Akil ASA; Macha MA; Haris M; Uddin S; Singh M; Bhat AA
J Transl Med; 2023 Jul; 21(1):449. PubMed ID: 37420216
[TBL] [Abstract][Full Text] [Related]
99. Orthogonal CRISPR screens to identify transcriptional and epigenetic regulators of human CD8 T cell function.
McCutcheon SR; Swartz AM; Brown MC; Barrera A; Amador CM; Siklenka K; Humayun L; Isaacs JM; Reddy TE; Nair S; Antonia S; Gersbach CA
bioRxiv; 2023 May; ():. PubMed ID: 37205457
[TBL] [Abstract][Full Text] [Related]
100. Genome Editing for Engineering the Next Generation of Advanced Immune Cell Therapies.
de Lima SCG; Fantacini DMC; Furtado IP; Rossetti R; Silveira RM; Covas DT; de Souza LEB
Adv Exp Med Biol; 2023; 1429():85-110. PubMed ID: 37486518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
